Whereas leukopenia was mainly attributed to the inhibition of BCL-2, inhibition of BCL-XL is presumably the major cause of thrombocytopenia observed upon ABT-263 treatment35. This evidence concerns the gene BCL2 and Decreased total leukocyte count.